0224 GMT - Medical-imaging tech-provider Pro Medicus needs to improve the visibility of its business pipeline or demonstrate an ability to speed up market-share gains in order to turn Macquarie analysts more positive on the stock. The analysts moderate their market-share assumption to 10% in fiscal 2027, from 11% previously. They say to clients in a note that they have largely factored in the announcement of further contract wins and renewals. Pro Medicus has yet to demonstrate material uptake of opportunities in adjacent specialities, such as cardiology, they say, adding that they see the stock as fairly valued following a recent de-rate. Macquarie trims its target price by 0.4% to A$257.40, maintaining a neutral rating. Shares are down 7.6% at A$210.405. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
March 26, 2025 22:24 ET (02:24 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.